Pure red cell aplasia during carbamazepine monotherapy

Brain and Development

Volumn 19, Issue 4, 1997, Pages 300-302

  Tagawa, Tetsuzo ^a   Sumi, Kiyoomi ^a   Uno, Risa ^a   Itagaki, Yusuke ^a   Fujii, Fumitoshi ^a   Yamaguchi, Hitoshi ^b  

^a OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^b OSAKA ROSAI HOSPITAL   (Japan)

Author keywords

Adverse reaction; Carbamazepine; Pure red cell aplasia

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; HEMOGLOBIN;

ANEMIA; ARTICLE; BONE MARROW EXAMINATION; CASE REPORT; CLONIC SEIZURE; DRUG WITHDRAWAL; EPILEPSY; ERYTHROBLAST; FEMALE; HUMAN; MEGAKARYOPOIESIS; MYELOPOIESIS; PURE RED CELL ANEMIA; RETICULOCYTOSIS; SCHOOL CHILD;

ANTICONVULSANTS; CARBAMAZEPINE; CHILD; EPILEPSY; FEMALE; HUMANS; RED-CELL APLASIA, PURE;

EID: 0030994415     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0387-7604(97)00580-9     Document Type: Article

References (19)

1. Pellock JM. Carbamazepine side effects in children and adults. Epilepsia 1987; 3: S64-S70.
2. Gram L, Jensen PK. Carbamazepine. Toxicity. In: Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK, editors. Antiepileptic Drugs. 3rd edition. New York: Raven Press, 1989: 555-565.
3. Pisciotta AV. Carbamazepine. Hematological toxicity. In: Woodbury DM, Penry JK, Pippenger CE, editors. Antiepileptic Drugs. New York: Raven Press, 1982: 533-541.
4. Hart RG, Easton JD. Carbamazepine and hematological monitoring. Ann. Neurol. 1982; 11: 309-312.
5. Freedman MH. Pure red cell aplasia in childhood and adolescence: pathogenesis and approaches to diagnosis. Br. J. Haematol. 1993; 85: 246-253.
6. Glader BF. Transient erythroblastopenia of childhood. In: Feig SA, Freedman MH, editors. Clinical Disorders and Experimental Models of Erythropoietic Failure. Florida: CRC Press, 1993: 69-84.
7. Freedman MH, Feig SA. Miscellaneous forms of acquired red cell aplasia and erythropoietic failure in childhood. In: Feig SA, Freedman MH, editors. Clinical Disorders and Experimental Models of Erythropoietic Failure. Florida: CRC Press, 1993: 129-144.
8. Krantz SB. Pure red cell aplasia: biology and treatment. In: Feig SA, Freedman MH, editors. Clinical Disorders and Experimental Models of Erythropoietic Failure. Florida: CRC Press, 1993: 85-127.
9. Brittingham TE, Lutcher CL, Murphy DL. Reversible erythroid aplasia induced by diphenylhydantoin. Arch. Intern Med. 1964; 113: 764-768.
10. Jeong Y-G, Jung Y, River GL. Pure RBC aplasia and diphenylhydantoin. J. Am. Med. Assoc. 1974; 229: 314-315.
11. Dessypris EN, Redline S, Harris JW, Krantz SB. Diphenylhydantoin-induced pure red cell aplasia. Blood 1985; 65: 789-794.
12. Kueh YK, Yeo TC, Choo MHH. Reversible pure red cell aplasia associated with diphenylhydantoin therapy. Ann. Acad. Med. Singapore 1991; 20: 407-409.
13. MacDougall LG. Pure red cell aplasia associated with sodium valproate therapy. J. Am. Med. Assoc. 1982; 247: 53-54.
14. Watts RG, Emanuel PD, Zucherman KS, Howard TH. Valproic acid-induced cytopenias: evidence for a dose-related suppression of hematopoiesis. J. Pediatr. 1990; 117: 495-499.
15. Hirai H. Two cases of erythroid hypoplasia caused by carbamazepine (Tegretol). Jpn. J. Clin. Hematol. 1977; 18: 338.
16. Nagae Y, Kato S. A case of pure red cell aplasia caused by carbamazepine. Bull. Nagoya City Hospital 1987; 10: 15-19.
17. Medberry CA, Pappas AA, Ackerman BH. Carbamazepine and erythroid arrest. Drug Intell. Clin. Pharm. 1987; 21: 439-441.
18. Buitendag DJ. Pure red-cell aplasia associated with carbamazepine. South Am. Med. J. 1990; 78: 214-215.
19. Yunis AA, Arimura GK, Lutcher CL, Blasquez J, Halloran M. Biochemical lesion in Dilantin-induced erythroid aplasia. Blood 1967; 30: 587-600.